1.3k total citations 39 papers, 1.1k citations indexed
About
Von Hoff is a scholar working on Oncology, Molecular Biology and Hematology.
According to data from OpenAlex, Von Hoff has authored 39 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Oncology, 10 papers in Molecular Biology and 10 papers in Hematology. Recurrent topics in Von Hoff's work include Cancer Treatment and Pharmacology (12 papers), Cancer therapeutics and mechanisms (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). Von Hoff is often cited by papers focused on Cancer Treatment and Pharmacology (12 papers), Cancer therapeutics and mechanisms (6 papers) and Colorectal Cancer Treatments and Studies (5 papers). Von Hoff collaborates with scholars based in United States and Belgium. Von Hoff's co-authors include Marcel Rozencweig, Franco M. Muggia, Martine Piccart, Young Rc, Richard L. Schilsky, Coltman Ca, Salmon Se, B Forseth, Daniel Glaubiger and Maxwell W. Layard and has published in prestigious journals such as PubMed and Munich Personal RePEc Archive (Ludwig Maximilian University of Munich).
In The Last Decade
Von Hoff
39 papers
receiving
960 citations
Author Peers
Peers are selected by citation overlap in the author's most active subfields.
citations ·
hero ref
This map shows the geographic impact of Von Hoff's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Von Hoff with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Von Hoff more than expected).
This network shows the impact of papers produced by Von Hoff. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Von Hoff. The network helps show where Von Hoff may publish in the future.
Co-authorship network of co-authors of Von Hoff
This figure shows the co-authorship network connecting the top 25 collaborators of Von Hoff.
A scholar is included among the top collaborators of Von Hoff based on the total number of
citations received by their joint publications. Widths of edges
represent the number of papers authors have co-authored together.
Node borders
signify the number of papers an author published with Von Hoff. Von Hoff is excluded from
the visualization to improve readability, since they are connected to all nodes in the network.
All Works
20 of 20 papers shown
1.
Hoff, Von. (1998). Promising new agents for treatment of patients with colorectal cancer.. PubMed. 25(5 Suppl 11). 47–52.10 indexed citations
2.
Hoff, Von, et al.. (1998). Alternative dosing schedules for irinotecan.. PubMed. 12(8 Suppl 6). 68–71.13 indexed citations
3.
Hoff, Von, et al.. (1986). Possible mitoxantrone-induced amenorrhea.. PubMed. 70(5). 659–61.9 indexed citations
4.
Weiss, Geoffrey R. & Von Hoff. (1985). Human tumor cloning assay: clinical applications for ovarian, gastric, pancreatic, and colorectal cancers.. PubMed. 12(3 Suppl 4). 69–74.5 indexed citations
5.
Hilgers, R.-D, et al.. (1985). Mitoxantrone in adenocarcinoma of the endometrium: a Southwest Oncology Group Study.. PubMed. 69(11). 1329–30.9 indexed citations
6.
Lathan, B., et al.. (1984). Use of a human tumor cloning system to evaluate analogs of methotrexate and mitoxantrone.. PubMed. 68(5). 733–8.23 indexed citations
7.
Hoff, Von, et al.. (1984). Comparison of the human tumor cloning and subrenal capsule assays.. PubMed. 44(3). 1087–90.33 indexed citations
8.
Ca, Coltman, et al.. (1984). Mitoxantrone in refractory nonHodgkin's lymphoma. A Southwest Oncology Group study.. PubMed. 11(3 Suppl 1). 50–3.31 indexed citations
9.
Hoff, Von, et al.. (1984). Bisantrene, an active drug in patients with advanced breast cancer.. PubMed. 68(2). 357–60.12 indexed citations
10.
Hoff, Von, et al.. (1982). Long-distance transportation of specimens for human tumor cloning.. PubMed. 2(2). 122–8.3 indexed citations
11.
Rb, Smith, et al.. (1982). Plasma and cerebrospinal fluid pharmacokinetics of acivicin in Ommaya reservoir-bearing rhesus monkeys.. PubMed. 66(6). 1333–41.11 indexed citations
12.
Hoff, Von, et al.. (1981). Uptake of melphalan by human ovarian carcinoma cells and its relationship to the amino acid content of ascitic fluid.. PubMed. 65(1-2). 157–61.7 indexed citations
13.
Se, Salmon & Von Hoff. (1981). In vitro evaluation of anticancer drugs with the human tumor stem cell assay.. PubMed. 8(4). 377–85.45 indexed citations
14.
Hoff, Von, et al.. (1980). Toxic effects of cis-dichlorodiammineplatinum(II) in man.. PubMed. 63(9-10). 1527–31.285 indexed citations
15.
Rozencweig, Marcel, et al.. (1978). Current trends and prospects in surgical adjuvant trials.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 48(7). 673–9.2 indexed citations
16.
Rozencweig, Marcel, et al.. (1978). Effective adjuvant treatments. A brief review of U.S. clinical trials.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 48(7). 653–8.1 indexed citations
17.
Hoff, Von, et al.. (1978). "Single"-agent activity of high-dose methotrexate with citrovorum factor rescue.. Munich Personal RePEc Archive (Ludwig Maximilian University of Munich). 62(2). 233–5.10 indexed citations
18.
Hoff, Von, et al.. (1978). Phase I study of methanesulfonamide, N-[4-(9-acridinylamino)-3-methoxyphenyl]-(m-AMSA) using a single-dose schedule.. PubMed. 62(10). 1421–6.34 indexed citations
19.
Rozencweig, Marcel, Von Hoff, & Franco M. Muggia. (1977). Investigational chemotherapeutic agents in head and neck cancer.. PubMed. 4(4). 425–9.24 indexed citations
20.
Hoff, Von, Marcel Rozencweig, & Franco M. Muggia. (1977). Cytembena: an anticancer drug with an unique structure.. PubMed. 26(6). 388–92.1 indexed citations
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive
bibliographic database. While OpenAlex provides broad and valuable coverage of the global
research landscape, it—like all bibliographic datasets—has inherent limitations. These include
incomplete records, variations in author disambiguation, differences in journal indexing, and
delays in data updates. As a result, some metrics and network relationships displayed in
Rankless may not fully capture the entirety of a scholar's output or impact.